GSK shares dive as weaker sales and mounting costs unnerve investors
British pharma company reports declining profits amid weaker vaccine sales and looming patent loss for blockbuster HIV drugBusiness live – latest updatesShares in GSK slid on Wednesday despite the UK drugmaker reporting better than expected financial results, as investors were unnerved by weaker… Sources: The Guardian.